Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database

Ying Li; Jianping Bi; Guoliang Pi; Hanping He; Yanping Li; Guang Han

doi:10.21037/atm-22-6481

Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database

Ann Transl Med. 2023 Feb 28;11(4):163. doi: 10.21037/atm-22-6481.

Authors

Ying Li^#¹, Jianping Bi^#¹, Guoliang Pi¹, Hanping He¹, Yanping Li¹, Guang Han¹

Affiliation

¹ Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

^# Contributed equally.

Abstract

Background: Immune checkpoint blockade (ICB) therapies have redefined human cancer treatment, including for head and neck squamous cell carcinoma (HNSCC). However, clinical responses to various immune checkpoint inhibitors are often accompanied by immune-related adverse events (irAEs). Therefore, it is crucial to obtain a comprehensive understanding of the association between different immune tumor microenvironments (TMEs) and the immunotherapeutic response.

Methods: The research data were obtained from The Cancer Genome Atlas (TCGA) database. We applied RNA-seq genomic data from tumor biopsies to assess the immune TME in HNSCC. As the TME is a heterogeneous system that is highly associated with HNSCC progression and clinical outcome, we relied on the Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) algorithm to calculate immune and stromal scores that were evaluated based on the immune or stromal components in the TME. Then, the Tumor Immune Dysfunction and Exclusion algorithm (TIDE) was used to predict the benefits of ICB to each patient. Finally, we identified specific prognostic tumor-infiltrating immune cells (TIICs) by quantifying the cellular composition of the immune response in HNSCC and its association to survival outcome, using the CIBERSORT algorithm.

Results: Utilizing the HNSCC cohort of the TCGA database and TIDE and ESTIMATE algorithm-derived immune scores, we obtained a list of microenvironment-associated lncRNAs that predicted different clinical outcomes in HNSCC patients. We validated these correlations in a different HNSCC cohort available from the TCGA database and provided insight into the prediction of response to ICB therapies in HNSCC.

Conclusions: This study confirmed that CD8⁺ T cells were significantly associated with better survival in HNSCC and verified that the top five significantly mutated genes (SMGs) in the TCGA HNSCC cohort were TP53, TTN, FAT1, CDKN2A, and MUC16. A high level of CD8⁺ T cells and high immune and stroma scores corresponded to a better survival probability in HNSCC.

Keywords: Head and neck squamous cell carcinoma (HNSCC); The Cancer Genome Atlas (TCGA); immune checkpoint blockade (ICB); tumor microenvironment (TME); tumor-infiltrating immune cell (TIIC).